Panacea-ml

Panacea-ml (Ra’anana Israel), a Ben-Gurion University spinoff, revolutionizes clinical trial design with its data-driven, explainable-AI SaaS platform. Addressing the primary causes of clinical development failure, Panacea-ml’s technology identifies patient profiles to maximize therapeutic efficacy, minimize safety risks, and improve participant retention. By leveraging historical clinical trials and its access to millions of electronic patient health records from real-world, Panacea-ml’s AI model helps pharmaceutical companies to enhance patient selection criteria, reduce cohort size, and uncover novel marker-endpoint interrelations, surrogate markers, and causal relationships beyond simple statistical correlations. Panacea-ml’s platform is a powerful tool for collaboration across development teams and accelerating drug development. In recent collaboration with pharma customers in neurodegenerative and rare disease clinical trials, Panacea-ml enabled a 30% reduction in participants without compromising statistical power and a 60% increase in patient retention. The platform also rescued a development program in diabetes after a failed Phase 3 trial. Panacea-ml is expanding into oncology and other difficult to power clinical trials and penetrate the UE market. Therefore, Panacea-ml is looking to raise $3 Millions in an Equity seed round.